Results 21 to 30 of about 52,096 (181)

Use of primaquine and glucose-6-phosphate dehydrogenase deficiency testing: Divergent policies and practices in malaria endemic countries. [PDF]

PLoS Neglected Tropical Diseases, 2018
Primaquine is the only available antimalarial drug that kills dormant liver stages of Plasmodium vivax and Plasmodium ovale malarias and therefore prevents their relapse ('radical cure').
Judith Recht, Elizabeth A Ashley, Nicholas J White   +2 more
doaj   +1 more source

Ultra-short course, high-dose primaquine to prevent Plasmodium vivax infection following uncomplicated pediatric malaria: A randomized, open-label, non-inferiority trial of early versus delayed treatment

International Journal of Infectious Diseases, 2023
Objectives: We aimed to assess safety, tolerability, and Plasmodium vivax relapse rates of ultra-short course (3.5 days) high-dose (1 mg/kg twice daily) primaquine (PQ) for uncomplicated malaria because of any Plasmodium species in children randomized to
Sze-Ann Woon, Brioni R. Moore, Moses Laman, Paula Tesine, Lina Lorry, Bernadine Kasian, Phantica Yambo, Gumul Yadi, William Pomat, Kevin T. Batty, Sam Salman, Leanne J. Robinson, Timothy M.E. Davis, Laurens Manning   +13 more
doaj   +1 more source

A model for malaria treatment evaluation in the presence of multiple species

Epidemics, 2023
Plasmodium falciparum and P. vivax are the two most common causes of malaria. While the majority of deaths and severe morbidity are due to P. falciparum, P.
C.R. Walker, R.I. Hickson, E. Chang, P. Ngor, S. Sovannaroth, J.A. Simpson, D.J. Price, J.M. McCaw, R.N. Price, J.A. Flegg, A. Devine   +10 more
doaj   +1 more source

Precarity at the Margins of Malaria Control in the Chittagong Hill Tracts in Bangladesh: A Mixed-Methods Study

Pathogens, 2020
Bangladesh has achieved significant progress towards malaria elimination, although health service delivery for malaria remains challenging in remote forested areas such as the Chittagong Hill Tracts (CHT).
Mohammad Abdul Matin, Nandini D. P. Sarkar, Ching Swe Phru, Benedikt Ley, Kamala Thriemer, Ric N. Price, Koen Peeters Grietens, Wasif Ali Khan, Mohammad Shafiul Alam, Charlotte Gryseels   +9 more
doaj   +1 more source

Characteristics of surgically resected non‐small cell lung cancer patients with post‐recurrence cure

Thoracic Cancer, 2020
Background The prognosis of postoperative recurrence in patients with non‐small cell lung cancer (NSCLC) is poor. However, depending on the recurrence patterns and treatment options, some patients can achieve long‐term survival following recurrence.
Dai Sonoda, Yosuke Matsuura, Yasuto Kondo, Junji Ichinose, Masayuki Nakao, Hironori Ninomiya, Yuichi Ishikawa, Makoto Nishio, Sakae Okumura, Yukitoshi Satoh, Mingyon Mun   +10 more
doaj   +1 more source

Global economic costs due to vivax malaria and the potential impact of its radical cure: A modelling study.

PLoS Medicine, 2021
BackgroundIn 2017, an estimated 14 million cases of Plasmodium vivax malaria were reported from Asia, Central and South America, and the Horn of Africa.
Angela Devine, Katherine E Battle, Niamh Meagher, Rosalind E Howes, Saber Dini, Peter W Gething, Julie A Simpson, Ric N Price, Yoel Lubell   +8 more
doaj   +1 more source

Implications of current therapeutic restrictions for primaquine and tafenoquine in the radical cure of vivax malaria. [PDF]

PLoS Neglected Tropical Diseases, 2018
The 8-aminoquinoline antimalarials, the only drugs which prevent relapse of vivax and ovale malaria (radical cure), cause dose-dependent oxidant haemolysis in individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency. Patients with
James Watson, Walter R J Taylor, Germana Bancone, Cindy S Chu, Podjanee Jittamala, Nicholas J White   +5 more
doaj   +1 more source

Increased primaquine total dose prevents Plasmodium vivax relapses in patients with impaired CYP2D6 activity: report of three cases

Malaria Journal, 2021
Background The relapsing nature of Plasmodium vivax infection is a major barrier to its control and elimination. Factors such as adequate dosing, adherence, drug quality, and pharmacogenetics can impact the effectiveness of radical cure of P.
Anielle de Pina-Costa, Ana Carolina Rios Silvino, Edwiges Motta dos Santos, Renata Saraiva Pedro, José Moreira, Gabriela Liseth Umana, Ana Danielle Tavares da Silva, Otília Helena Lupi da Rosa Santos, Karina Medeiros de Deus Henriques, Cláudio Tadeu Daniel-Ribeiro, Patrícia Brasil, Tais Nobrega Sousa, André M. Siqueira   +12 more
doaj   +1 more source

Vivax malaria in pregnancy and lactation: a long way to health equity

Malaria Journal, 2020
Background The Sustainable Development Goals (SDG) call for increased gender equity and reduction in malaria-related mortality and morbidity. Plasmodium vivax infections in pregnancy are associated with maternal anaemia and increased adverse perinatal ...
Tobias Brummaier, Mary Ellen Gilder, Gornpan Gornsawun, Cindy S. Chu, Germana Bancone, Mupawjay Pimanpanarak, Kesinee Chotivanich, François Nosten, Rose McGready   +8 more
doaj   +1 more source

Modelling primaquine-induced haemolysis in G6PD deficiency

eLife, 2017
Primaquine is the only drug available to prevent relapse in vivax malaria. The main adverse effect of primaquine is erythrocyte age and dose-dependent acute haemolytic anaemia in individuals with glucose-6-phosphate dehydrogenase deficiency (G6PDd).
James Watson, Walter RJ Taylor, Didier Menard, Sim Kheng, Nicholas J White   +4 more
doaj   +1 more source